Recommended Antiviral Therapy and Monitoring for Chronic Hepatitis B
Patients with chronic hepatitis B and HBV DNA >2,000 IU/ml plus elevated ALT (>ULN) and/or significant fibrosis should receive antiviral therapy with first-line nucleoside/nucleotide analogues (entecavir or tenofovir), while those with cirrhosis require treatment if HBV DNA is detectable at any level, regardless of ALT. 1
Treatment Indications: A Clear Algorithm
The 2025 EASL guidelines provide the most current framework 1:
Immediate Treatment Required:
HBeAg-positive or HBeAg-negative chronic hepatitis B with:
- HBV DNA >2,000 IU/ml AND
- ALT >ULN AND/OR
- Significant fibrosis present
Cirrhosis patients: Treat if HBV DNA is detectable at any level, regardless of ALT or viral load 1
Advanced fibrosis (Metavir >F3 or liver stiffness >8 kPa): Can treat with any detectable HBV DNA, regardless of ALT 1
Consider Treatment:
- Persistently low HBV DNA (<2,000 IU/ml) with persistently elevated ALT—but first exclude other liver diseases 1
First-Line Antiviral Selection
Use entecavir or tenofovir as initial therapy 2, 3. These agents offer:
- High potency for viral suppression
- High genetic barrier to resistance
- Excellent long-term safety profile
- Wide availability as generics 1
Avoid lamivudine as first-line therapy due to high resistance rates when long-term treatment is anticipated 4, 5.
Pegylated interferon can be considered in select patients without contraindications, as it offers a finite treatment duration and higher chance of sustained off-treatment response 4, though nucleoside/nucleotide analogues remain the standard approach for most patients.
Monitoring Strategy
During Treatment:
Monitor every 3 months for patients on nucleoside/nucleotide analogues 4:
- Serum HBV DNA (quantitative)
- ALT levels
- HBeAg/anti-HBe status (if initially HBeAg-positive)
Critical pitfall: Frequent HBV DNA monitoring is essential for early detection of viral breakthrough, which may indicate emerging resistance 5. An increase of ≥1 log₁₀ IU/ml from nadir warrants genotypic resistance testing 4.
For Untreated Patients:
Monitoring frequency depends on viral load and HBeAg status 4:
- High viraemia (HBV DNA ≥20,000 IU/ml): Every 3-6 months
- Lower viraemia (<20,000 IU/ml):
- HBeAg-positive: Every 3-6 months
- HBeAg-negative: Every 6-12 months
HCC Surveillance:
All patients with cirrhosis or increased cirrhosis risk require hepatocellular carcinoma surveillance every 6 months with right upper quadrant ultrasound and alpha-fetoprotein 6.
Treatment Duration
HBeAg-positive patients: Continue nucleoside/nucleotide therapy until HBeAg seroconversion occurs, HBV DNA drops below 80 IU/ml, and this is maintained for 6 months during therapy 4.
HBeAg-negative patients: Usually require prolonged or indefinite treatment, as safe stopping points remain unclear 4. The goal is sustained viral suppression to prevent disease progression, cirrhosis, and hepatocellular carcinoma 1, 3.
Managing Resistance
If viral breakthrough occurs (≥1 log₁₀ increase in HBV DNA from nadir):
- Confirm with repeat testing
- Obtain genotypic resistance testing 4
- Add a second non-cross-resistant agent rather than switching monotherapy 4, 5
This "add-on" strategy is superior to switching and prevents further resistance development 5.
Clinical Outcomes
Long-term viral suppression with nucleoside/nucleotide analogues achieves:
- Prevention of disease progression and HCC 1
- Reversal of fibrosis and cirrhosis 1
- Clinical recompensation in advanced liver disease 1
- Enhanced survival 1
Common pitfall: Patient adherence is essential for adequate viral suppression 3. Emphasize the importance of continuous therapy to prevent resistance and disease progression.